
|Articles|May 1, 2003
Corticosteroid shown to be safe for long-term SAC control
Author(s)Charles Slonim, MD, Chet Scerra
Tampa, FL-Loteprednol etabonate ophthalmic suspension 0.2% (Alrex, Bausch & Lomb Pharmaceuticals and Pharmos Corp.), the first corticosteroid specifically designed for signs and symptoms of seasonal allergic conjunctivitis (SAC), is safe for long-term use, according to a recent multicenter study.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Dr. Mali’s top 5 predictions in ophthalmology for 2026
2
Low-dose pilocarpine shrinks pupil without altering accommodation in presbyopia
3
FDA clears Novaliq’s Investigational New Drug application for NOV05
4
Q&A: What’s in the glaucoma treatment pipeline?
5



























